AP214
Phase 2Small molecule
AP214 is one of 19 small molecule programs targeting Kidney Injury. It is currently in Phase 2.
1
Indications
3
Total Trials
0
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
21 competitors in Kidney Injury
#DrugCompanyPhaseTrials
1Ketalar
AAultman Health Foundation
Approved
Zofran
NovartisPhase 3
Cysteine Hydrochloride
NovartisPhase 3
Aldactone
PfizerPhase 3
Kytril
CConrado Roberto Hoffmann Filho
Phase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Aloxi
AAvyxa
Phase 3
Letairis
GileadPhase 2
Imdur
OOmnivium
Phase 2
Giapreza
LLa Jolla Pharmaceutical Company
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cardiac Surgery2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AP214. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAction Pharma A/S